<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166691">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927719</url>
  </required_header>
  <id_info>
    <org_study_id>H-406-005</org_study_id>
    <nct_id>NCT00927719</nct_id>
  </id_info>
  <brief_title>Safety Surveillance Study of ACAM2000® Vaccinia Vaccine</brief_title>
  <official_title>A Phase IV Enhanced Safety Surveillance Study of ACAM2000® in Military Personnel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an enhanced safety surveillance study that will occur within the military Service
      Member population.

      Primary Objective:

        -  To evaluate the rates of suspected, probable, and confirmed myocarditis and/or
           pericarditis in temporal association with ACAM2000® vaccination.

      Secondary Objectives:

        -  To evaluate the rates of cardiovascular adverse events in temporal association with
           ACAM2000® vaccination.

        -  To evaluate the rates of neurological adverse events in temporal association with
           ACAM2000® vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Armed Forces Health Surveillance Activity (AFHSA) will perform comprehensive health
      surveillance through the operation of the Defense Medical Surveillance System (DMSS).
      Demographic and medical information gathered within monthly reports from the DMSS will be
      collected from approximately 100,000 to 200,000 military Service Members who received the
      ACAM2000® smallpox vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the safety following vaccination with ACAM2000® vaccinia vaccine</measure>
    <time_frame>Entire study duration</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Smallpox</condition>
  <arm_group>
    <arm_group_label>ACAM2000® vaccinia vaccine Cohort</arm_group_label>
    <description>Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACAM2000® smallpox vaccine</intervention_name>
    <description>Previous vaccination, no vaccine is administered in this study.</description>
    <arm_group_label>ACAM2000® vaccinia vaccine Cohort</arm_group_label>
    <other_name>ACAM2000®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants that had received ACAM2000®, vaccinia virus Smallpox vaccine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Male and female military personnel &gt;= 17 years of age.

          -  Have received the ACAM2000® smallpox vaccine.

        Exclusion Criteria :
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Registry Sanofi Pasteur</last_name>
    <email>RegistryContactUs@sanofipasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Twentynine Palms</city>
        <state>California</state>
        <zip>92278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft Campbell</city>
        <state>Kentucky</state>
        <zip>42223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Bliss</city>
        <state>Texas</state>
        <zip>79906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Hood</city>
        <state>Texas</state>
        <zip>76544</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 16, 2016</lastchanged_date>
  <firstreceived_date>June 24, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smallpox</keyword>
  <keyword>Smallpox Vaccine</keyword>
  <keyword>Vaccinia virus</keyword>
  <keyword>Military</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
